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Abstract: Magnetic microspheres (MMS) used for magnetic 
drug targeting consist of magnetic nanoparticles (MNP) and a 
pharmaceutical agent embedded in a polymeric matrix 
material. The application of MNP for drug targeting enables 
guiding the MMS to a target area, imaging the position of the 
MMS with magnetic particle imaging, and finally inducing 
drug release. As latter takes place by degradation of the MMS 
or diffusion through the matrix, an increase in temperature, 
e.g. through magnetic hyperthermia, leads to an accelerated 
drug release. Here, MMS consisting of poly(lactic-co-
glycolic)acid (PLGA) with different monomer ratios were 
prepared by an oil-in-water emulsion evaporation method. The 
model drug Camptothecin (CPT) and magnetic multicore 
nanoparticles (MCNP) with a high specific heating rate were 
embedded into the microspheres. We obtained MMS in the 
preferred size range of 1 to 2 µm with a concentration of 
MCNP of 16wt%, a drug load of about 0.5wt% and an 
excellent heating performance of 161 W/gMMS. Investigations 
of the drug release behaviour showed an accelerated drug 
release when increasing the temperature from 20 °C to 37 °C 
or 43 °C by using a water bath. In addition, an increase in drug 
release of about 50% through magnetic heating of the MMS 
up to 44 °C compared to 37 °C was observed. By this, a 
magnetic hyperthermia induced CPT release from PLGA 
MMS is demonstrated for the very first time. 
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1 Introduction 
The treatment of tumours with chemotherapy leads to severe 
side effects due to the systemic distribution of the anti-cancer 
drug and the resulting damage to healthy tissue. To deliver the 
therapeutic agent specifically to a desired area, so called drug 
delivery systems consisting of polymeric drug carriers are a 
promising approach [1]. Often, microspheres (MS) in the size 
range from 1 to 5 µm are used as such carriers whereby natural 
polymers (e.g. proteins or polysaccharides) or synthetic ones 
(e.g. poly(ethylene glycol)) can be used [2]. A very commonly 
used synthetic polymer is poly(lactide-co-glycolide) because 
of its biodegradability and FDA approval [3-7].  
To guide the drug carriers to their target area inside the 
human body, embedding magnetic nanoparticles (MNP) into 
the MS is an advantageous tool. By applying an external field, 
they can be moved inside the body while their current position 
can be determined by imaging via MPI or MRI. Additionally, 
MNP can generate heat by magnetic hyperthermia when they 
are exposed to an alternating magnetic field [8]. Since drugs 
are released out of the polymeric matrix by either degradation 
or diffusion, an increase in temperature can accelerate this 
process [9]. Those additional features can’t be offered by other 
targeting strategies like antibody targeting [6].  
In order to enable a fast and reliable temperature increase, 
MNP with a high specific heating power are needed. For this, 
magnetic multicore nanoparticles (MCNP) [10, 11], which 
show high magnetization values in an external field and at the 
same time low aggregation tendencies due to their low 
coercivity once the external field is removed, are used.  
In the here presented study MCNP have been embedded 
into PLGA microspheres, prepared by an oil-in-water 
emulsion evaporation method [12] using different PLGA with 
varying monomer ratios (lactide:glycolide). As a therapeutic 
agent, the anticancer drug Camptothecin (CPT) was added to 
the microspheres. Morphology and magnetic properties of the 
MMS were investigated and the temperature dependent drug 
release was studied. To our knowledge, this is the first time the 
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combination of PLGA microspheres, magnetic multicore 
nanoparticles and Camptothecin is evaluated.  
2 Methods 
2.1 Preparation of microspheres 
PLGA microspheres were prepared using an oil-in-water 
emulsion evaporation method [12]. Three different types of 
PLGA (purchased from Sigma Aldrich) were used to study the 
influence of the lactide to glycolide ratio on the drug release. 
Used ratios were 50:50, 65:35 and 75:25. In short, 200 mg of 
PLGA were dissolved in dichlormethane as an organic solvent. 
MCNP were coated with C12-bisphosphonate to ensure a 
stable suspension in organic solvents [13] and added to the 
PLGA solution at a ratio of 1:5 (MCNP:PLGA). CPT was 
dissolved in dimethylsulfoxid at a ratio of 1:100 (CPT:PLGA) 
and added to the PLGA/MCNP suspension to form the organic 
phase. The total volume of the organic phase was adjusted to 
2 ml. As a water phase, 15 ml of a 2wt% aqueous 
polyvinylalcohol solution was used. The two phases were then 
homogenized by using a mechanical dispersing tool at varying 
velocities for 2 minutes to form micro droplets. The emulsion 
was then poured in a large volume (85 ml) of the aqueous 
phase and stirred for 6 hours under a fume hood to evaporate 
the organic solvent and thereby harden the micro droplets to 
form magnetic microspheres (MMS). Those microspheres 
were extracted via centrifugation or magnetic separation and 
washed several times with deionized water. For long term 
storage the MMS were freeze dried.  
2.2 Characterization 
To evaluate the size and size distribution of the MMS, 
static light scattering (Mastersizer 2000, Malvern Panalytical, 
Almelo, Netherlands) was used.  
Size and size distribution was also investigated with 
scanning electron microscopy (SEM; FEI Helios NanoLap G3 
UC, Hillsboro, Oregon, USA) which also allows statements on 
the morphology of the MMS. By enhancing the contrast for 
heavy elements and preparing cross sections with a focused 
ion beam the MCNP can be located. Additionally X-Ray 
spectroscopy (EDX) for carbon, oxygen and iron with E0 = 
3 keV was used to determine the composition on the 
microspheres surface and at the centre of the cross section.  
For magnetic characterisation of the MCNP and the MMS 
a vibrating sample magnetometer was used (VSM; MicroMag 
3900, Princeton Measurements, Princeton, USA). 
Heating performance (specific absorption rate; SAR) of 
the MMS was evaluated by using calorimetric measurements 
as described before [14]. For this, MMS were dispersed in 
water at different concentrations and a magnetic field of 
24 kA/m and 410 kHz was applied. The temperature rise was 
measured with a fiberoptic probe (FOTEMP2, Optocon, 
Dresden, Germany). 
To study the temperature dependent drug release, aliquots 
of 2 mg CPT loaded MMS were dispersed in 2 ml PBS 
(pH = 7.4) and stored at room temperature or in water baths 
with 37 °C and 43 °C. The remaining drug content in the MMS 
was determined at certain time points by dissolving the MMS 
in an organic solvent. CPT concentration in this solution was 
measured via UV/VIS spectroscopy at the absorption 
maximum for Camptothecin at 364 nm using a calibration 
curve. It was made sure that no other involved chemical agent 
showed a significant absorption at this measurement 
wavelength. To show the acceleration of drug release through 
magnetic heating, aliquots of 10 mg CPT loaded MMS in 
0.5 ml PBS were stored at 37 °C or heated up to 44 °C 
magnetically for one hour. Remaining drug content was 
measured as described above. 
3 Results and Discussion 
SEM images of the MMS showed a perfectly round 
morphology for all microspheres loaded with CPT and MCNP 
(see Figure 1). The mean size of the MMS was in the desired 
range with values of 1.3 to 1.8 µm measured with the 
mastersizer. Homogenization speed had no significant 
influence on the mean size taking into account the invariable 
peaks of the size distributions of the MMS derived from SEM 
images. However, looking at the width of the size distribution, 
an increasing homogenization speed leads to a narrower 
distribution without altering the peak (see Figure 2).
Figure 1: SEM image of MMS 
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Concerning the location of the MCNP inside the MMS the 
FIB cross sections revealed the particles to be mostly located 
on the surface of the MMS. X-Ray spectra confirmed these 
findings by showing a larger intensity for iron than for carbon 
on the surface, whereas the cross section through the 
microspheres has a very low Fe concentration.  
 Drug loaded MS showed an initial amount of CPT up to 
0.5wt%. Drug release studies at room temperature, 37 °C and 
43 °C done by water bath heating revealed a clear dependency 
between temperature and drug release kinetics. In general, a 
burst type drug release was observed especially for 37 and 
43 °C, with fast release of CPT in the first hours followed by 
a plateau phase, as expected from the literature [5, 12]. After 
196 h, about 80% of the initial drug load was released for 
37 °C and 43 °C whereas at room temperature a maximum of 
50% was released. The main difference between 37 and 43 °C 
is the significantly faster drug release that can be seen in the 
first hours (see Figure 3). The influence of increasing 
temperature on the drug release matches with literature [9]. In 
contrast, the PLGA type has a minor influence on the drug 
release behaviour and from the fast drug release within hours, 
a diffusion based release mechanism can be deduced since 
polymer degradation happens in weeks to months. 
VSM data show a coercivity of 3.7 kA/m for the MMS, 
which matches the values measured for the pure MCNP, and 
indicates a ferrimagnetic behaviour. From the saturation 
magnetization of 11.6 Am²/kg for the MMS, a concentration 
of 16wt% is determined for the MCNP inside the MMS, which 
relates to an encapsulation efficiency of nearly 97%.  
 SAR measurements showed a very promising heating 
power of the MMS (see Figure 4). At a concentration of 
2.5wt% MMS in water, which is a realistic value for 
application, temperature increased by 10 K in 20 seconds and 
an SAR of 161 W/gMMS was calculated.  
As a proof of principle, accelerated drug release through 
magnetic heating was demonstrated. MMS heated up to 44 °C 
for one hour in a magnetic field, significantly (p=0.0001) 
released 48,7% more drug than MMS stored at 37 °C.  
4 Conclusion and Outlook 
 In this study, we prepared perfectly spherically shaped PLGA 
microspheres with a main size of 1 to 2 µm, loaded with 
Camptothecin and magnetic multicore nanoparticles. MCNP 
are mainly located at the surface of the MMS and enable 
heating the MMS with an external magnetic field, whereby a 
SAR of 161 W/gMMS is obtained. Drug release kinetics show a 
clear dependency on the temperature by an acceleration and a 
higher overall release when temperature is increased. By 
heating the MMS magnetically up to 44 °C for one hour, 50% 
Figure 2: Size distribution derived from SEM images for two 
different homogenization velocities. Intervals cover the stated 
value ±0,25 µm 
Figure 3: Drug release kinetics for different PLGA types in the 
first 10 hours. Lines only serve as a guide to the eye 
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more drug is released comparing to MMS stored at 37 °C. First 
attempts to manipulate and move the MMS with a magnetic 
field gradient or a rotating magnetic field within an MPI 
scanner showed promising results. In following studies, the 
targeting efficiency has to be characterized quantitatively. Our 
findings confirm the concept of using polymeric microspheres 
for drug delivery and controlling the drug release via magnetic 
heating.  
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